Patent Assignment
Reel/Frame 036283/0189
Change of Name
Recorded: 2015-08-05
Pages: 7
Assignor
CUBIST PHARMACEUTICALS, INC.
Executed: 2015-06-29
Assignee
CUBIST PHARMACEUTICALS LLC
2000 GALLOPING HILL ROAD, KENILWORTH, NEW JERSEY, 07033
Covered Properties
(55)
Aminoacyl Adenylate Mimics as Novel Antimicrobial and Antiparasitic Agents
Patent:
5,726,195 →
Application:
08/683,809 →
Methods for Generating and Screening Novel Metabolic Pathways
Patent:
5,783,431 →
Application:
08/738,944 →
Enterococcal Aminoacyl-Trna Synthetase Proteins, Nucleic Acids and Strains Comprising Same
Patent:
6,221,640 →
Application:
08/855,910 →
Methods for Generating and Screening Novel Metabolic Pathways
Patent:
6,242,211 →
Application:
09/263,352 →
Methods for Administration of Antibiotics
Patent:
6,468,967 →
Application:
09/406,568 →
Anhydro-And Isomer-a-21978C Cyclic Peptides
Patent:
39,071 →
Application:
09/547,357 →
High Purity Lipopeptides, Lipopeptide Micelles and Processes for Preparing Same
Patent:
6,696,412 →
Application:
09/735,191 →
Novel Lipopeptides as Antibacterial Agents
Novel Lipopeptides as Antibacterial Agents
Novel Lipopeptides as Antibacterial Agents
Compositions and Methods for Increasing the Oral Absorption of Antimicrobials
Methods for Administration of Antibiotics
Novel Lipopeptides as Antibacterial Agents
High Purity Lipopeptides
Therapeutic Compositions
Daptomycin for the Treatment of Biofilm and Catheter Salvage
Methods for Preparing Purified Lipopeptides
Compositions and Methods for Increasing the Oral Absorption of Antimicrobials
Novel Antibacterial Agents for the Treatment of Gram Positive Infections
High Purity Lipopeptides
High Purity Lipopeptides
CB-183,315 Compositions and Related Methods
Application:
13/481,009 →
Publication:
US 2013/0109633
Lipopeptide Compositions and Related Methods
1,3,4-Oxadiazole and 1,3,4-Thiadiazole Beta-Lactamase Inhibitors
1,3,4-Oxadiazole and 1,3,4-Thiadiazole Beta-Lactamase Inhibitors
1,3,4-Oxadiazole and 1,3,4-Thiadiazole Beta-Lactamase Inhibitors
1,3,4-Oxadiazole and 1,3,4-Thiadiazole Beta-Lactamase Inhibitors
1,3,4-Oxadiazole and 1,3,4-Thiadiazole Beta-Lactamase Inhibitors
Isoxazole Beta-Lactamase Inhibitors
1,2,4-Oxadiazole and 1,2,4-Thiadiazole Beta-Lactamase Inhibitors
Beta-Lactamase Inhibitors
High Purity Lipopeptides
Methods for Preparing Purified Lipopeptides
Methods for Preparing Purified Lipopeptides
Cephalosporin Compound
Patent:
8,809,314 →
Application:
14/020,230 →
Lipopeptide Compositions and Related Methods
Crystalline Form of a Beta-Lactamase Inhibitor
Beta-Lactamase Inhibitors
Isoxazole Beta-Lactamase Inhibitors
Application:
14/260,184 →
Publication:
US 2014/0323459
Cephalosporin Compound
Application:
14/333,966 →
Publication:
US 2015/0025053
High Purity Lipopeptides
Methods for Preparing Purified Lipopeptides
Application:
14/500,469 →
Publication:
US 2015/0183830
Crystalline Form of a Beta-Lactamase Inhibitor
Application:
14/504,786 →
Publication:
US 2015/0111864
B-Lactamase Inhibitor Picoline Salt
Beta-Lactamase Inhibitors
Application:
14/505,432 →
Publication:
US 2015/0038478
Isoxazole Beta-Lactamase Inhibitors
Application:
14/505,436 →
Publication:
US 2015/0038479
Isoxazole Beta-Lactamase Inhibitors
Application:
14/505,438 →
Publication:
US 2015/0038482
1,3,4-Oxadiazole and 1,3,4-Thiadiazole Beta-Lactamase Inhibitors
Application:
14/505,442 →
Publication:
US 2015/0031659
1,3,4-Oxadiazole and 1,3,4-Thiadiazole Beta-Lactamase Inhibitors
Application:
14/505,445 →
Publication:
US 2015/0031665
1,2,4-Oxadiazole and 1,2,4-Thiadiazole Beta-Lactamase Inhibitors
Application:
14/505,450 →
Publication:
US 2015/0031660
1,2,4-Oxadiazole and 1,2,4-Thiadiazole Beta-Lactamase Inhibitors
Application:
14/505,453 →
Publication:
US 2015/0031666
Therapeutic Compositions
Application:
14/592,526 →
Publication:
US 2015/0165029
Method for Screening Lyophilized Parenteral Formulations
Application:
14/701,229 →
Publication:
US 2015/0316568
Method for Screening Lyophilized Parenteral Formulations
Application:
61/986,537 →
CCR9 Antagonist Compounds
Application:
62/031,889 →
Related Assignments
(9)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Agreement
Nov 20, 2012
From: CUBIST PHARMACEUTICALS, INC.; ADOLOR CORPORATION; CALIXA THERAPEUTICS, INC.; CUBIST PHARMACEUTICALS HOLDINGS, INC.
To: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
Reel/Frame 029339/0669 →
Assignment of Assignor's Interest
Jan 15, 2014
From: KEITH, DENNIS; LAI, JAN-JI; GOVARDHAN, CHANDRIKA; KHALAF, NAZER
To: CUBIST PHARMACEUTICALS, INC.
Reel/Frame 031974/0035 →
Assignment of Assignor's Interest
Jul 2, 2015
From: CUBIST PHARMACEUTICALS, INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 035969/0613 →
Release of Security Interest
Jul 24, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: CALIXA THERAPEUTICS, INC.; ADOLOR CORPORATION; CUBIST PHARMACEUTICALS, INC.
Reel/Frame 036180/0070 →
Nunc Pro Tunc Assignment
Aug 6, 2015
From: CUBIST PHARMACEUTICALS LLC
To: MERCK SHARP & DOHME CORP.
Reel/Frame 036268/0626 →
Security Interest
Aug 12, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: CUBIST PHARMACEUTICALS, INC.; ADOLOR CORPORATION; CALIXA THERAPEUTICS, INC.
Reel/Frame 036308/0207 →
Corrective Assignment to Correct the Nature of Conveyance Previously Recorded at Reel: 036308 Frame: 0207. Assignor(S) Hereby Confirms the Release of Security Interest.
Aug 14, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: CUBIST PHARMACEUTICALS, INC.; ADOLOR CORPORATION; CALIXA THERAPEUTICS, INC.
Reel/Frame 036355/0184 →
Change of Address
Sep 14, 2016
From: CUBIST PHARMACEUTICALS LLC
To: CUBIST PHARMACEUTICALS LLC
Reel/Frame 040026/0743 →
Merger
Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →